Hanna John Walter JR sold $1.2M of CDNA

Hanna John Walter JR (President and CEO) sold 40,000 shares of CareDx, Inc. (CDNA) at an average of $29.24 ($29.00–$29.24, $1.17M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jun 30, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest information is the specific sale size, price range, and that it occurred under a pre-arranged 10b5-1 plan; this typically has limited fundamental impact but can influence short-term sentiment.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone does not change the company’s fundamentals.

03

What to watch

The article does not disclose any concurrent changes in guidance, contracts, or clinical/operational milestones—so the trading signal should be treated as sentiment-only.

Relevance 5/10Novelty 5/10Timing: after-hours/filing date (2026-06-30) for the latest insider-sale disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA) by its President and CEO, Hanna John Walter Jr.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO sold about 40,000 shares in open-market transactions at ~$29.00–$29.24, per a newly filed SEC Form 4.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a routine Form 4 open-market sale under a pre-arranged 10b5-1 plan; it provides timing/size but no new operating or financial information.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/liquidity needs rather than bearish expectations.

Key entities

  • CareDx, Inc.

    Issuer of the Form 4 insider transaction; CEO sold shares in open-market trades.

  • Hanna John Walter Jr

    President and CEO who executed the reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.